Afirma基因组测序分类器(GSC)的真实世界性能:一项Meta分析
该Meta分析比较Afirma GSC在真实世界研究与2018年验证研究中的性能。真实世界研究中GSC的敏感性97%、观察特异度88%、观察阳性预测值65%、阴性预测值99%,保守特异度80%、保守阳性预测值49%,除敏感性和保守阳性预测值外均显著高于验证研究。真实世界良性呼叫率67%高于验证研究的54%(P < 0.05)。
要点
- 真实世界GSC敏感性97%、阴性预测值99%,适合用于排除恶性。
- 真实世界观察特异度88%、观察阳性预测值65%,均显著高于验证研究。
- 真实世界良性呼叫率67%高于验证研究的54%(P < 0.05)。
核心结论
- Afirma GSC的真实世界数据在观察特异度和观察阳性预测值上显著优于验证研究,提示切除的GSC可疑结节中癌症检出率增加。
- 较高的良性呼叫率可能增加以临床观察替代手术的总体比例。
研究设计与样本
- 本研究为Meta分析,比较真实世界验证后研究与2018年GSC验证研究的性能指标。
- 分析纳入至少1例分子良性结果患者接受手术的研究进入敏感性、特异度和阴性预测值分析;未手术的分子良性结果视为真阴性;未手术的可疑结果在观察分析中排除或保守分析中视为假阳性;非浸润性滤泡性甲状腺肿瘤伴乳头状核特征视为恶性。
主要发现
- 真实世界研究中GSC敏感性97%、观察特异度88%、观察阳性预测值65%、阴性预测值99%。
- 保守真实世界性能显示保守特异度80%、保守阳性预测值49%。
- 真实世界研究良性呼叫率67%高于验证研究的54%(P < 0.05)。
- 除敏感性和保守阳性预测值外,真实世界其余指标均显著高于验证研究。
关键数值与推荐
- 2018年GSC验证研究报道敏感性91%、特异度68%、阳性预测值47%、阴性预测值96%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The Afirma® GSC aids in risk stratifying indeterminate thyroid nodule cytology (ITN). The 2018 GSC validation study (VS) reported a sensitivity (SN) of 91%, specificity (SP) of 68%, positive predictive value (PPV) of 47%, and negative predictive value (NPV) of 96%. Since then, 13 independent real-world (RW) postvalidation studies have been published. OBJECTIVE: This study's objective is to compare the RW GSC performance to the VS metrics. METHODS: Rules and assumptions applying to this analysis include: (1) At least 1 patient with molecular benign results must have surgery for that study to be included in SN, SP, and NPV analyses. (2) Molecular benign results without surgical histology are considered true negatives (TN) (as are molecular benign results with benign surgical histology). (3) Unoperated patients with suspicious results are either excluded from analysis (observed PPV [oPPV] and observed SP [oSP]) or assumed histology negatives (false positives; conservative PPV [cPPV] and conservative SP [cSP]) 4. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features is considered malignant. RESULTS: In RW studies, the GSC demonstrates a SN, oSP, oPPV, and NPV of 97%, 88%, 65%, 99% respectively, and conservative RW performance showed cSP of 80% and cPPV of 49%, all significantly higher than the VS except for SN and cPPV. There was also a higher benign call rate (BCR) of 67% in RW studies compared to 54% in the VS (P < 0.05). CONCLUSION: RW data for the Afirma GSC demonstrates significantly better oSP and oPPV performance than the VS, indicating an increased yield of cancers for resected GSC suspicious nodules. The higher BCR likely increases the overall rate of clinical observation in lieu of surgery.
引用
- Nasr CE, Andrioli M, Endo M, et al. Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)-A Meta-analysis. J Clin Endocrinol Metab. 2023. PMID: 36470585. doi:10.1210/clinem/dgac688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。